{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:49:00Z","timestamp":1787024940068,"version":"build-2736575974"},"reference-count":60,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.2217\/fon-2023-0964","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T04:45:26Z","timestamp":1707194726000},"page":"703-715","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus"],"prefix":"10.1080","volume":"20","author":[{"given":"Barbara J","family":"Klencke","sequence":"first","affiliation":[{"name":"Sierra Oncology, a GSK company, San Mateo, CA94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafe","family":"Donahue","sequence":"additional","affiliation":[{"name":"Sierra Oncology, a GSK company, San Mateo, CA94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[{"name":"GSK plc, Philadelphia, PA19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7635-7846","authenticated-orcid":false,"given":"Catherine","family":"Ellis","sequence":"additional","affiliation":[{"name":"GSK plc, Philadelphia, PA19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Sierra Oncology, a GSK company, San Mateo, CA94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Strouse","sequence":"additional","affiliation":[{"name":"GSK plc, Philadelphia, PA19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26857"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv203"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S53348"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_3_9_12_1","unstructured":"World Health Organization . Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/85839\/WHO_NMH_NHD_MNM_11.1_eng.pdf (Accessed 24October2023)."},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0028-x"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.016"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"e_1_3_9_19_1","volume-title":"64th ASH Annual Meeting & Exposition","author":"Gerds AT","year":"2022","unstructured":"Gerds AT , HarrisonC , ThompsonSet al. The burden of illness and the incremental burden of transfusion dependence in myelofibrosis in the United States. Presented at: 64th ASH Annual Meeting & Exposition. New Orleans, LA, USA, 10\u201313 December 2022 (Poster 1729)."},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002662"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01157-4"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_9_27_1","unstructured":"GSK . Press release. www.gsk.com\/en-gb\/media\/press-releases\/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia\/ (Accessed 24October2023)."},{"key":"e_1_3_9_28_1","unstructured":"Ojjaara [momelotinib] . Prescribing information. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA-PI-PIL.PDF (Accessed 24October2023)."},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010151"},{"key":"e_1_3_9_30_1","volume-title":"64th ASH Annual Meeting & Exposition.","author":"Mohan SR","year":"2022","unstructured":"Mohan SR , OhST , AliHet al. A phase 1\/2 study of INCB000928 as monotherapy or combined with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF). Presented at: 64th ASH Annual Meeting & Exposition.New Orleans, LA, USA, 10\u201313 December 2022 (Poster 1714)."},{"key":"e_1_3_9_31_1","volume-title":"61st ASH Annual Meeting & Exposition.","author":"Gerds AT","year":"2019","unstructured":"Gerds AT , VannucchiAM , PassamontiFet al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. Presented at: 61st ASH Annual Meeting & Exposition.Orlando, FL, USA, 7\u201310 December 2019 (Oral presentation 557)."},{"key":"e_1_3_9_32_1","volume-title":"62nd ASH Annual Meeting & Exposition.","author":"Gerds A","year":"2020","unstructured":"Gerds A , VannucchiAM , PassamontiFet al. Duration of response to luspatercept in patients (pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF) \u2013 updated data from the phase 2 ACE-536-MF-001 study. Presented at: 62nd ASH Annual Meeting & Exposition.Virtual, 5\u20138 December 2020 (Oral presentation 2992)."},{"key":"e_1_3_9_33_1","volume-title":"63rd ASH Annual Meeting & Exposition.","author":"Mesa R","year":"2021","unstructured":"Mesa R , HarrisonC , KiladjianJet al. INDEPENDENCE: a Phase III study of efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring red blood cell transfusions. Presented at: 63rd ASH Annual Meeting & Exposition.Atlanta, GA, USA, 11\u201314 December 2021 (Poster 1490)."},{"key":"e_1_3_9_34_1","unstructured":"ClinicalTrials.gov . www.clinicaltrials.gov\/ct2\/show\/NCT04472598 (Accessed 24October2023)."},{"key":"e_1_3_9_35_1","unstructured":"ClinicalTrials.gov . www.clinicaltrials.gov\/ct2\/show\/NCT04468984 (Accessed 24October2023)."},{"key":"e_1_3_9_36_1","volume-title":"64th ASH Annual Meeting & Exposition.","author":"Harrison C","year":"2022","unstructured":"Harrison C , KremyanskayaM , BosePet al. Pelabresib (CPI-0610) as add-on to ruxolitinib in myelofibrosis: durability of response and safety beyond week 24 in the phase 2 MANIFEST study. Presented at: 64th ASH Annual Meeting & Exposition.New Orleans, LA, USA, 10\u201313 December 2022 (Poster 4344)."},{"key":"e_1_3_9_37_1","volume-title":"65th ASH Annual Meeting & Exposition.","author":"Rampal R","year":"2023","unstructured":"Rampal R , GrosickiS , ChraniukDet al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study. Presentated at: 65th ASH Annual Meeting & Exposition.San Diego, CA, USA, 9\u201312 December 2023 (Oral 628)."},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.015"},{"key":"e_1_3_9_41_1","volume-title":"64th ASH Annual Meeting & Exposition.","author":"Verstovsek S","year":"2022","unstructured":"Verstovsek S , OhS , KiladijianJ-Jet al. Transfusion independence response as a potential surrogate for overall survival in JAKi-experienced patients with myelofibrosis from MOMENTUM. Presented at: 64th ASH Annual Meeting & Exposition.New Orleans, LA, USA, 10\u201313 December 2022 (Poster 3028)."},{"key":"e_1_3_9_42_1","volume-title":"10th Annual Meeting of the Society of Hematologic Oncology.","author":"Oh S","year":"2022","unstructured":"Oh S , MesaR , HarrisonCet al. Retrospective analysis of anemia benefit of pacritinib from the PERSIST-2 trial. Presented at: 10th Annual Meeting of the Society of Hematologic Oncology.Houston, TX, USA, 28 September\u2013 1 October 2022 (Poster MPN-145)."},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908892"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00435"},{"key":"e_1_3_9_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910182"},{"key":"e_1_3_9_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113380"},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113379"},{"key":"e_1_3_9_48_1","unstructured":"Jesduvroq (daprodustat) . Prescribing information. GlaxoSmithKline; 2023. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Jesduvroq\/pdf\/JESDUVROQ-PI-MG.PDF (Accessed 24October2023)."},{"key":"e_1_3_9_49_1","unstructured":"Reblozyl (luspatercept-aamt) . Prescribing information. Bristol Myers Squibb; 2022. https:\/\/packageinserts.bms.com\/pi\/pi_reblozyl.pdf (Accessed 24October2023)."},{"key":"e_1_3_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_3_9_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133331"},{"key":"e_1_3_9_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7549.1080"},{"key":"e_1_3_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14003"},{"key":"e_1_3_9_54_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2017-1155"},{"issue":"2","key":"e_1_3_9_55_1","first-page":"94","article-title":"Influence of a light meal on routine haematological tests","volume":"8","author":"Lippi G","year":"2010","unstructured":"Lippi G , Lima-OliveiraG , SalvagnoGLet al. Influence of a light meal on routine haematological tests. Blood Transfus.8(2), 94\u201399 (2010).","journal-title":"Blood Transfus."},{"key":"e_1_3_9_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000773"},{"key":"e_1_3_9_57_1","volume-title":"64th ASH Annual Meeting & Exposition.","author":"Mascarenhas J","year":"2022","unstructured":"Mascarenhas J , GerdsA , KiladijianJet al. PACIFICA: a randomized, controlled Phase III study of pacritinib versus physician\u2019s choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia. Presented at: 64th ASH Annual Meeting & Exposition.New Orleans, LA, USA, 10\u201313 December 2022 (Poster 4316)."},{"key":"e_1_3_9_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01637-7"},{"key":"e_1_3_9_59_1","volume-title":"EHA2023 Hybrid Congress.","author":"Harrison C","year":"2023","unstructured":"Harrison C , MesaR , TalpazMet al. Reduction in red blood cell transfusion burden: a novel longitudinal time-dependent analysis in patients with transfusion-dependent myelofibrosis treated with momelotinib. Presented at: EHA2023 Hybrid Congress.Frankfurt, Germany, 8\u201311 June 2023 (Poster P1044)."},{"key":"e_1_3_9_60_1","volume-title":"ASCO Annual Meeting 2023.","author":"Mesa RA","year":"2023","unstructured":"Mesa RA , PalandriF , VerstovsekSet al. Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2). Presented at: ASCO Annual Meeting 2023.Chicago, IL, USA, 2\u20138 June 2023 (Poster 7066)."},{"key":"e_1_3_9_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_3_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003364"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T10:22:10Z","timestamp":1726741330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.2217\/fon-2023-0964"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0964","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}